semaglutide patent expiry europe Ozempic's Protection Starts to Expire in 2026. What Next? The semaglutide story: highlighting the

As discussed below, the development of unimolecular multi-agonists that stimulate GLP-1 receptors and other receptors such as GIP receptors and glucagon receptors (GCGR) can have beneficial effects on metabolism and increase metabolic rate at tolerable doses [57]

Other weight loss treatments are available on the NHS, so it's likely to be approved for use, but we do not know when

Rapid weight loss changes estrogen levels, and the hormonal shifts that accompany significant fat loss can temporarily alter cycle timing, flow, and symptoms

Slow and steady loss is more sustainable

Researchers have observed that patients prescribed semaglutide, the active ingredient in both drugs, had an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION)